This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense CI
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes CI
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating MT
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study CI
IceCure Medical Ltd. Announces Results from an Independent Study CI
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study CI
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company?s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda?S Prior Denial of Icecure?S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer CI
Sector Update: Health Care Stocks Fall Premarket Tuesday MT
IceCure Medical Regains Nasdaq Compliance MT
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients CI
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense CI
Transcript : IceCure Medical Ltd, Q3 2023 Earnings Call, Nov 15, 2023
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer CI
IceCure Medical Ltd. Announces in Parallel with the Growing Adoption of ProSense(R) CI
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System CI
IceCure Medical Receives Minimum Bid Noncompliance Notice From Nasdaq MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Advancing Late Wednesday Afternoon MT
Sector Update: Health Care Stocks Rising Wednesday Afternoon MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates MT
Chart IceCure Medical Ltd
More charts
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
More about the company
  1. Stock Market
  2. Equities
  3. ICCM Stock
  4. ICCM Stock
  5. News IceCure Medical Ltd
  6. Sector Update: Health Care Stocks Lower but Resisting Steep Declines